FDA accepts Afresa NDA

FDA accepted for filing an NDA from MannKind Corp. (NASDAQ:MNKD) for Afresa to treat Type I and Type II diabetes. MannKind said FDA has not yet assigned a PDUFA date. The company has requested Priorit...